You can buy or sell CBAY and other stocks, options, and ETFs commission-free!
CymaBay Therapeutics Inc. Common Stock, also called CymaBay Therapeutics, is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. The listed name for CBAY is CymaBay Therapeutics Inc. Common Stock.
52 Week High
52 Week Low
— per share
Expected Mar 11, After Hours